Lokelma is a new type of potassium binding compound, to be ingested orally to lower overall potassium levels in high risk populations.
Patients with diabetic nephropathy and impaired kidney function have increased urinary excretion of albumin and a poor renal and cardiovascular prognosis. As albuminuria is viewed both as a risk marker but also as a target for intervention, any treatment with antiproteinuric effects will be beneficial.
Potassium has been shown to be a modulating marker impacting response to renin-angiotensin system (RAAS) blocking treatment and long-term outcome, i.e. whenever potassium is elevated (>4.5 mEq/l) the efficacy of RAAS blockade is hampered. Dietary restrictions are often not sufficient to decrease potassium levels.
To investigate whether concomitant treatment with Lokelma can improve the efficacy of standard RAAS blockade which otherwise can be hampered by the presence of hyperkalemia.
Medical Department, University Hospital Zealand, Sygehusvej 10, 4000 Roskilde.
Njursektionen, Specialmedicin, Akademiska Sjukhuset Uppsala.